Skip to main content

Type 1 diabetes devices and technology

medwireNews

10-18-2023 | Type 1 diabetes | News

Automated insulin delivery benefits type 1 diabetes individuals at high hypoglycemia risk

Automated insulin delivery reduces hypoglycemia in people with type 1 diabetes at increased risk, improving their time spent in target glucose range.

06-02-2023 | Type 1 diabetes | News

Pregnancy-specific closed-loop system proves feasible for home use

Results of a pilot study show that a hybrid closed-loop insulin delivery system customized for pregnancy used by women with type 1 diabetes at home significantly improved their glucose outcomes.

05-19-2023 | Type 1 diabetes | News

Over 60s with type 1 diabetes show trust in Cambridge hybrid closed-loop system

The use of the Cambridge hybrid closed-loop insulin delivery system by older adults with type 1 diabetes mellitus is associated with “improved quality of life,” says an international team of researchers.

04-05-2023 | Flash glucose monitoring | News

Reduced acute complications for young people using CGM

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

03-30-2023 | Artificial pancreas systems | News

Virtual closed-loop initiation success in very young children

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

02-28-2023 | Flash glucose monitoring | News

Real-world isCGM benefits shown for people with psychosocial diabetes issues

People with high diabetes distress achieve reductions in glycated hemoglobin and the need for emergency care for acute diabetes complications after starting on intermittently scanned continuous glucose monitoring, report researchers.

02-15-2023 | Flash glucose monitoring | News

ALERTT1: rtCGM alarm benefits persist in long term

The benefits of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes are sustained for at least 2 years, shows the extension of the ALERTT1 study.

Close up oF device for continuous glucose monitoring in blood – CGM

12-15-2022 | Continuous glucose monitoring | News

Eliminating CGM cost barriers reduces disparities in use

Fully subsidizing continuous glucose monitors could overcome disparities in their use by people with diabetes, suggests research conducted in adults enrolled in a US Medicaid program.

09-23-2022 | EASD 2022 | Conference coverage | News

Bolus timing requires more attention in people using advanced technologies for type 1 diabetes

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

09-21-2022 | EASD 2022 | Conference coverage | News

isCGM benefits sustained for at least 2 years

The improved glycemic control gained from use of intermittently scanned continuous glucose monitoring is sustained for at least 2 years in people with type 1 diabetes, show real-world data.

Girl with CGM

09-21-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

09-21-2022 | EASD 2022 | Conference coverage | News

Libre upgrade illustrates power of hypoglycemia alerts

Gaining the use of a low blood glucose alert by switching from the FreeStyle Libre 1 to 2 reduces the amount of time people with type 1 diabetes spend in hypoglycemia, report researchers.

09-20-2022 | EASD 2022 | Conference coverage | News

Insulin pump delivery may reduce fatty liver risk in type 1 diabetes

Using an insulin pump rather than multiple daily injections may help protect people with type 1 diabetes from developing fatty liver disease, report researchers.

09-07-2022 | Pathogenesis | News

CLOuD: Early and sustained closed-loop therapy does not stave off beta-cell decline

Starting young people on closed-loop insulin delivery within 21 days after type 1 diabetes diagnosis does not slow the decline in their C-peptide levels over the next 12 months, report the CLOuD investigators.

09-07-2022 | Artificial pancreas systems | News

AHCL system benefits people with poorly controlled type 1 diabetes

Use of the MiniMed 780G advanced hybrid closed-loop system leads to greater reductions in glycated hemoglobin levels than conventional treatment in people with poorly controlled type 1 diabetes, ADAPT study data show.

09-06-2022 | Artificial pancreas systems | News

Closed-loop control may support neurodevelopment in adolescents

Improved glycemic control with hybrid closed-loop insulin delivery may facilitate the typical neurodevelopmental changes that occur during adolescence for those with type 1 diabetes, suggests a proof-of-concept trial.

08-16-2022 | Continuous glucose monitoring | News

Parents give thumbs up to remote CGM initiation

Most parents of children starting continuous glucose monitoring soon after their type 1 diabetes diagnosis find virtual initiation to be convenient and effective, shows a small study.

07-06-2022 | Artificial pancreas systems | News

Hybrid closed-loop system brings benefits even with lax bolusing

Use of the Tandem Control IQ hybrid closed-loop insulin delivery system improves time in range even for users who very rarely bolus for meals or to treat hyperglycemia, an observational study suggests.

07-01-2022 | Flash glucose monitoring | News

Flash monitoring initiation may boost mental health

An observational study suggests that initiating flash glucose monitoring might lead to a reduction in symptoms of depression in people with insulin-treated diabetes.

06-13-2022 | Artificial pancreas systems | News

Researchers calculate unannounced snack threshold for closed-loop system

Children and adolescents using an advanced hybrid closed-loop system for type 1 diabetes can tolerate an unannounced snack containing 20 g of carbohydrate without excessive blood sugar fluctuations, Italian researchers report.